ProGnosis Biotech S A

« Previous article
Rapid Antigen Test f...

25th January 2021  Content supplied by: ProGnosis Biotech S.A

Rapid Test Ag 2019-nCov: Prevent COVID-19 from Spreading!

Rapid Test Ag 2019-nCov is a lateral flow test with high sensitivity for the detection of SARS-CoV-2 antigen (nucleocapsid protein) in nasopharyngeal swab specimens.

The test helps to rapidly identify infected individuals, enabling prompt clinical decisions and preventing a potential virus outbreak. Rapid Test Ag 2019-nCov is an effective tool for large-scale testing; it does not require any special instrument and can be used in all types of premises. A simple method that produces real-time results in 15 mins! The test has received the CE-IVD mark.

Clinical Performance Characteristics
In a clinical performance conducted with 613 specimens (prior confirmed with RT-PCR assay), the Rapid Test Ag 2019-nCov showed: 95.56% sensitivity & 99.58% specificity.

Applications of Rapid Test Ag 2019-nCov

  • Healthcare
  • Ports of entry
  • Working & operating environments
  • Appropriate from mass screening

The Rapid Test Ag 2019-nCov is now listed in the IVD Devices, and Test Methods Database of the European Commission, the German Federal Institute for Drugs and Medical Devices (in accordance with the standards set by Robert-Koch- and Paul Ehrlich Institutes) and is also registered in the Italian Ministry of Health. 

Please note: Test should only be conducted by medical personnel

Watch Testing Procedure: 

Share on:


Date Published: 25th January 2021

Source article link: View

View full company details